RxSight(RXST) Plunges 37.84% on Lowered Revenue Outlook

RxSight(RXST) shares plummeted by 37.84%, hitting a record low today with an intraday decline of 50.59%.

RxSight's stock price has been significantly impacted by a series of disappointing financial and operational results. The company's share price experienced a substantial drop following the announcement of a lowered full-year revenue outlook. The preliminary second quarter 2025 revenue fell to approximately $33.6 million, representing a 4% year-over-year decrease and an 11% sequential decline. Notably, there was a dramatic 45% quarterly and 49% yearly drop in Light Delivery Device (LDD) placements, indicating challenges in market penetration and adoption. Consequently, RxSight revised its 2025 revenue guidance downward to $120-130 million from the previous $160-175 million, reflecting a potential year-over-year decline.

Despite a strong financial position with $227.5 million in cash and investments, these operational challenges and the reduction in revenue guidance have led to multiple analyst downgrades and a pessimistic forecast for the company's stock. The company's struggles in market penetration and adoption of its LDD technology have raised concerns among investors about its long-term viability and growth prospects. The significant drop in LDD placements suggests that RxSight may need to reassess its market strategy and product offerings to regain investor confidence and stabilize its stock price.